Consent to Migration

RNS Number : 2547Q

Uniphar PLC

25 February 2021

 

UNIPHAR PLC CONSENTS TO THE MIGRATION OF ORDINARY SHARES TO EUROCLEAR BANK'S CENTRAL SECURITIES DEPOSITORY

Dublin, London | 25 February 2021

As previously announced, the shareholders of the Company approved resolutions in relation to the replacement of CREST with a system operated by Euroclear Bank for the electronic settlement of trading in Uniphar Shares at the extraordinary general meeting held on 15 February 2021 ("EGM").

In accordance with Resolution 1 approved at the EGM, on 16 February 2021 a committee of the board of directors of the Company approved the Company giving its consent to the Migration of the Migrating Shares to Euroclear Bank's central securities depository in accordance with the Migration of Participating Securities Act 2019.  The requisite notifications in connection with the Migration have also been made by the Company to the Irish Companies Registration Office and Euronext Dublin.

The Migration will take place as part of the wider Market Migration which will occur on the date determined by Euronext Dublin and which is currently expected to be on or around 15 March 2021. Further announcements will be made in relation to the Migration timetable in due course.

--- ENDS ---

For further details contact:

Uniphar	[phone]
Brian O'Shaughnessy
Group Director of Corporate Development	[e-mail]
Davy	[phone]
(Joint Corporate Broker, Nominated Adviser and Euronext Growth Adviser)
Fergal Meegan
Barry Murphy
Orla Cowzer
RBC Capital Markets (Joint Corporate Broker)	[phone]
Darrell Uden
Jonathan Hardy
Jamil Miah
Stifel Nicolaus Europe Limited (Joint Corporate Broker)	[phone]
Matt Blawat
Ben Maddison
Francis North
Q4 PR	[phone] or
(Public Relations Adviser to Uniphar)	[phone]
Iarla Mongey

About Uniphar plc  

Headquartered in Dublin, Ireland, Uniphar plc is an international diversified healthcare services business, servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Commercial & Clinical, Product Access and Supply Chain & Retail.

The Group has strong established relationships with 7 of the top 10 pharma companies and 6 of the top 10 medical device companies. With more than 2,500 colleagues, the Group is active in Ireland, the UK, the Benelux, the Nordics and the US, delivering unlicensed and specialty medicine on a global basis.

The Group's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar represents a strong combination of scale, growth and profitability.

Commercial & Clinical

In Commercial & Clinical the Group provides sales, marketing & distribution solutions to multinational pharmaceutical and medical device manufacturers on an outsourced basis. Active in Ireland, the UK, the Benelux, and the Nordics, the Group is growing with its clients to provide pan-European solutions. Uniphar has built a fully integrated multi-channel solution that is supported by highly experienced, clinically trained teams to deliver exceptional outcomes for all clients.

Product Access

In Product Access the Group is growing two distinct service offerings: 1) "On Demand Access", which are pharmacy led solutions for sourcing and supplying unlicensed medicines to meet the needs of both retail and hospital pharmacists; and 2) "Exclusive Access", which are manufacturer led solutions for controlling the release of speciality medicines for specifically approved patient populations in agreed markets. The Group currently delivers product access solutions on a global basis.

Supply Chain & Retail

Uniphar is an established market leader in Ireland with over a 50% market share in the wholesale/hospital market, supported by a network of c.335 owned, franchised and symbol group pharmacies. The business supports the diverse customer base through the provision of strong service levels coupled with innovative commercial initiatives. Supply Chain & Retail is an Irish only business for the Group, although the manufacturer relationships and infrastructure are utilised for the benefit of the growth divisions, Commercial & Clinical and Product Access.

 

END

 

 

MSCUSVNRAVUUUAR